Vor Bio reports positive telitacicept trial results in kidney disease

May 14, 2026 8:30 AM

Vor Bio (NASDAQ: VOR) announced that results from a Phase 3 trial of telitacicept for IgA nephropathy were published in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found